Article · 5 Oct 2026
Conference abstract
Free to sell your biosimilar? The effect of the new FDA rules
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Even after obtaining regulatory clearance, can a biosimilar manufacturer sell a biosimilar drug in the US? Intellectual property (IP) and the new FDA rules present many obstacles to such sales. These obstacles fall into three major categories: trade secrets, freedom to operate (non-infringement) and patents. Trade secrets of the biosimilar manufacturer may be revealed to its most direct competition, as details of the biosimilar manufacturer?s own process may be revealed to the innovator company, as part of the new FDA rules. Freedom to operate may be blocked by submarine patents, which are US patents filed before 1995 and which remain secret until issuance. Last year, Amgen?s newly issued submarine patent (valid until 2028) for the biological drug Enbrel? surprised the world. This submarine patent is a real show stopper for companies interested in manufacturing such a biosimilar. Ascertaining FTO is also expensive and complex, as the BPCIA imposes requirements on both the innovator and biosimilar manufacturer to identify and disclose relevant patents, and conduct a back and forth discussion on the potential infringement aspects thereof. Finally, the biosimilar manufacturer needs to consider whether to attempt to protect its own intellectual property, for example for the process, through a patent, or whether to maintain this as a trade secret. Thus, biosimilar manufacturers face many more IP challenges than current generic drug manufacturers.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioequivalence & Bioavailability.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioequivalence & Bioavailability
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “D?vorah Graeser”